DOCSLIB.ORG

RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020 Guidelines RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020 Rajeev Chawla1, S. V. Madhu2, B. M. Makkar3, Sujoy Ghosh4, Banshi Saboo5, Sanjay Kalra6, On behalf of the RSSDI-ESI Consensus Group* 1North Delhi Diabetes Centre, Rohini, New Delhi, 2Centre for Diabetes, Endocrinology and Metabolism, UCMS-GTB Hospital, 3Dr. Makkar’s Diabetes and Obesity Centre, Paschim Vihar, New Delhi, 4Department of Endocrinology and Metabolism, Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal, 5DiaCare - A Complete Diabetes Care Centre, Ahmedabad, Gujarat, 6Department of Endocrinology, Bharti Hospital, Karnal, Haryana, India *RSSDI-ESI CONSENSUS GROUP Diagnosis of Diabetes Coordinators: S. R. Aravind, Ganapathi Bantwal Members: A. H. Zargar Nihal Thomas, Alok Kanugo Prevention (Including Screening and Coordinators: S. V. Madhu, R. M. Anjana Early Detection) Members: A. Ramachandran, Eesh Bhatia, Amitesh Agarwal Treatment 1: Medical Nutrition Therapy Coordinators: Anoop Misra, Naval Vikram, and Lifestyle Modification Members: Parminder Singh, Sambit Das, Vageesh Ayyar Treatment 2: Oral Antidiabetic Agents Coordinators: Shashank Joshi, Krishna Seshadri Members: Vijay Panikar, Sameer Agarwal, V. Sringesh Treatment 3: Injectables Coordinators: A. K. Das, Sanjay Agarwal Members: Ajay Kumar, Sunil Jain, Sujit Jha Treatment 4: Individualizing Therapy Coordinators: Banshi Saboo, A. K. Singh Members: Muralidharan, Santosh Singh, Rajesh Khadgawat Post Prandial Hyperglycaemia Coordinators: Hari Kumar, Kaushik Pandit Members: S. K. Sharma, Mathew John, Pradip Mukhopadhyay Acute Metabolic Complications Coordinators: Jubin Jacob, Anil Bhansali Members: Sushil Jindal, Kamlakar Tripathi, Narsingh Verma Hypoglycaemia Coordinators: Anand Moses, Jamal Ahmed Members: D. C. Sharma, G. Vijaykumar, Dheeraj Kapoor Chronic Complications 1: Retinopathy, Coordinators: Rajeev Chawla, Rakesh Sahay Neuropathy, Diabetic Kidney Disease Members: Shalini Jaggi, R. K. Lalwani, Hitesh Punyani Chronic Complications 2: Diabetic Foot Coordinators: S. K. Singh, Vijay Vishwanathan and Peripheral Arterial Disease Members: Ashu Rastogi, Ghanshyam Goyal, Ashraf Ganie Contd... Address for correspondence: Prof. S.V. Madhu, Director-Professor and Head, Department of Endocrinology and Head, Centre for Diabetes, Endocrinology and Metabolism, UCMS-GTBHospital, New Delhi, India. E-mail: [email protected] This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution‑NonCommercial‑ShareAlike 4.0 License, which allows others to Access this article online remix, tweak, and build upon the work non‑commercially, as long as appropriate credit Quick Response Code: is given and the new creations are licensed under the identical terms. Website: www.ijem.in For reprints contact: [email protected] How to cite this article: Chawla R, Madhu SV, Makkar BM, Ghosh S, DOI: Saboo B, Kalra S. RSSDI-ESI clinical practice recommendations for the 10.4103/ijem.IJEM_225_20 management of type 2 diabetes mellitus 2020. Indian J Endocr Metab 2020;24:1-122. © 2020 Indian Journal of Endocrinology and Metabolism | Published by Wolters Kluwer - Medknow 1 Chawla, et al.: RSSDI-ESI clinical practice recommendations Diabetes and CVD Coordinators: V. Mohan, Arvind Gupta Members: Shaileja Kale, Sudhir Bhandari, R. V. Jayakumar Obesity and Type 2 Diabetes Mellitus Coordinators: B. M. Makkar, Neeta Deshpande, Members: C. L Nawal, K. A. V. Subramanian, Rucha Mehta Infections and Vaccinations Coordinators: Subhankar Chowdhary, Jayant Panda Members: Pramod Gandhi, J. K. Sharma, Vinay Dhandhania Sexual Dysfunction Coordinators: Samar Banerjee, P. K. Jabbar Members: Mithun Bhartiya, Urman Dhruv, Premlata vartakavi Glycaemic Monitoring Coordinators: Siddhartha Das, A. G. Unnikrishnan Members: Rajiv Kovil, Alok Sachan, Girish Varma Technologies Coordinators: Jothydev, Ambrish Mithal Members: K. M. Prasanna Kumar, Manoj Chawla, Ameya Joshi Special Situations Coordinators: Nikhil Tandon, Padma Menon Members: Sujoy Ghosh, Nalini Shah, Usha Sriram, Rajesh Rajput Fasting and diabetes Coordinators: Sarita Bajaj, Manas Barua Members: M. K. Garg, Sachin Chhitawar, Hemant Thacker Education Coordinators: Vasanth Kumar, Sunil Gupta Members: Meena Chhabra, Amit Gupta, G. D. Ramchandani Psychosocial Issues Coordinators: H. B. Chandalia, Sanjay Kalra Members: G. R. Sridhar, Rishi Shukla, Salam Ranabir Complementary and Alternate Therapies Coordinators: P. V. Rao, Anuj Maheshwari Members: J. P. Sai, K. R. Narsimha Setty, Saurabh Srivastava DIAGNOSIS OF DIABETES RECOMMENDATIONS Recommended Care Prediabetes can be diagnosed with any of the following criteria • Impaired fasting glucose (IFG): FPG 100 mg/dL to 125 mg/dL or • Impaired glucose tolerance (IGT): 2-h plasma glucose (2-h PG) during 75-g OGTT 140 mg/dL to 199 mg/dL or • HbA1c ≥5.7%-6.4% Diabetes can be diagnosed with any of the following criteria: • FPG ≥126 mg/dL* or • FPG ≥126 mg/dL and/or 2-h PG ≥200 mg/dL using 75-g OGTT • HbA1c≥6.5% ** or • Random plasma glucose ≥200 mg/dL in the presence of classical diabetes symptoms Asymptomatic individuals with a single abnormal test should have the test repeated to confirm the diagnosis unless the result is unequivocally abnormal. Limited Care Diabetes can be diagnosed with any of the following criteria: • FPG ≥126 mg/dL* or • FPG ≥126 mg/dL and/or 2-h plasma glucose ≥200 mg/dL using 75-g OGTT or • Random plasma glucose ≥200 mg/dL in the presence of classical diabetes symptoms Asymptomatic individuals with a single abnormal test should have the test repeated to confirm the diagnosis unless the result is unequivocally abnormal NOTE • Plasma must be separated soon after collection because • Estimation of HbA1c should be performed using NGSP the blood glucose levels drop by 5%–8% hourly if whole standardized method. blood is stored at room temperature. • Capillary glucose estimation methods are not recommended for diagnosis For more details on glucose estimation visit: http://www.ncbi. • Venous plasma is used for estimation of glucose nlm.nih.gov/books/NBK248/ 2 Indian Journal of Endocrinology and Metabolism ¦ Volume 24 ¦ Issue 1 ¦ January-February 2020 Chawla, et al.: RSSDI-ESI clinical practice recommendations *FPG is defined as glucose estimated after no caloric intake RATIONALE AND EVIDENCE for at least 8–12 hours. Glycosylated haemoglobin cut off for diagnosis of diabetes **Using a method that is National Glycohaemoglobin in Indian patients Standardization Program (NGSP) certified. For more on • The RSSDI expert panel suggests HbA1c and NGSP, please visit http://www.ngsp.org/index. ▫ HbA1c ≥6.5% as optimal level for diagnosis of asp diabetes in Indian patients ▫ HbA1c cannot be used as ‘sole’ measurement for BACKGROUND diagnosis of diabetes in Indian settings. The diagnostic criteria of diabetes have been constantly These recommendations are based on the Indian evolving. Both type 1 and type 2 Diabetes mellitus (DM) evidences are diagnosed based on the plasma glucose criteria, either • A recent study conducted in Singapore residents the fasting plasma glucose (FPG) levels or the 2-h plasma of Chinese, Malay and Indian race to assess the post-prandial glucose (2-h PPG) levels during a 75-g oral performance of HbA1c as a screening test in Asian glucose tolerance test (OGTT), or the newer glycosylated populations suggested that HbA1c is an appropriate haemoglobin (HbA1c) criteria which reflects the average alternative to FPG as a first-step screening test, and a plasma glucose concentration over the previous 8–12 combination of HbA1c with a cut-off of ≥6.1% and FPG weeks.[1,2] The International Expert Committee Report level ≥100 mg/dL would improve detection in patients recommend a cut-point of ≥6.5% for HbA1c for diagnosing with diabetes.[6] diabetes as an alternative to fasting plasma glucose (FPG • A study to assess the diagnostic accuracy and optimal [3] ≥7.0 mmol/L). HbA1c testing has some substantial HbA1c cutoffs for diabetes and prediabetes among high- advantages over FPG and OGTT, such as convenience, risk south Indians suggested that HbA1c ≥6.5% can pre-analytical stability, and less day-to-day fluctuations be defined as a cut-off for diabetes and HbA1c ≥5.9% due to stress and illness.[3] Additionally, HbA1c has is optimal for prediabetes diagnosis and value <5.6% been recognized as marker to assess secondary vascular excludes prediabetes/diabetes status.[8] complications due to metabolic derailments in susceptible • Data from a community based randomized cross sectional individuals.[2,4,5] However, given ethnic differences in sensitivity and specificity of HbA1c population-specific study in urban Chandigarh suggest that HbA1c cut point cut-offs might be necessary.[6,7] Moreover, measuring of 6.5% has optimal specificity of 88%, while cut off HbA1c is expensive as compared to FPG assessments and point of 7.0% has sensitivity of 92% for diagnosis of [10] standardization of measurement techniques and laboratories diabetes. are poorly practiced across the country.[8] Also, in several • The results of the Chennai Urban Rural Epidemiology countries including India, HbA1c demonstrated inadequate Study (CURES) demonstrated 88.0% sensitivity and predictive accuracy in the diagnosis of diabetes, there is 87.9% specificity for detection of diabetes when HbA1c no consensus on a suitable cut-off point of HbA1c for cut off point is 6.1% (based on 2-h post load plasma diagnosis of diabetes in this high-risk population.[9]
Load more

Recommended publications
  • Exendin-4 Peptide Analogues As Dual Glp-1/Gip Receptor Agonists
    (19) TZZ¥ZZ_Z_T (11) EP 3 080 150 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07K 14/575 (2006.01) C07K 14/605 (2006.01) 01.08.2018 Bulletin 2018/31 (86) International application number: (21) Application number: 14828149.6 PCT/EP2014/077336 (22) Date of filing: 11.12.2014 (87) International publication number: WO 2015/086728 (18.06.2015 Gazette 2015/24) (54) EXENDIN-4 PEPTIDE ANALOGUES AS DUAL GLP-1/GIP RECEPTOR AGONISTS EXENDIN-4-PEPTIDANALOGA ALS DUALE GLP-1/GIP-REZEPTORAGONISTEN ANALOGUES PEPTIDIQUES D’EXENDINE-4 EN TANT QU’AGONISTES DU RÉCEPTEUR GIP/GLP-1 DOUBLE (84) Designated Contracting States: (74) Representative: Weickmann & Weickmann AL AT BE BG CH CY CZ DE DK EE ES FI FR GB PartmbB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO Postfach 860 820 PL PT RO RS SE SI SK SM TR 81635 München (DE) (30) Priority: 13.12.2013 EP 13306712 (56) References cited: WO-A1-2012/167744 WO-A2-2009/035540 (43) Date of publication of application: US-A1- 2011 166 062 US-A1- 2012 196 802 19.10.2016 Bulletin 2016/42 • JOHN L. KRSTENANSKY ET AL: "Importance of (73) Proprietor: SANOFI the 10-13 region of glucagon for its receptor 75008 Paris (FR) interactionsand activation of adenylate cyclase", BIOCHEMISTRY, vol. 25, no. 13, 1 July 1986 (72) Inventors: (1986-07-01), pages 3833-3839, XP055117918, • KADEREIT, Dieter ISSN: 0006-2960, DOI: 10.1021/bi00361a014 65926 Frankfurt am Main (DE) • VICTOR A.
    [Show full text]
  • Renato Wilberto Zilli Eficácia Em Longo Prazo Das
    RENATO WILBERTO ZILLI EFICÁCIA EM LONGO PRAZO DAS GLIFLOZINAS VERSUS GLIPTINAS NO TRATAMENTO DO DIABETES MELLITUS TIPO 2 APÓS FALÊNCIA DA METFORMINA COMO MONOTERAPIA: REVISÃO SISTEMÁTICA E METANÁLISE EM REDE Tese apresentada ao Programa de Ciências Médicas da Faculdade de Medicina da Universidade de São Paulo para obtenção do título de Doutor em Ciências. Área de Concentração: Processos Imunes e Infecciosos Orientador: Prof. Dr. Fabiano Pinheiro da Silva (Versão corrigida. Resolução CoPGr 6018/11, de 13 de outubro de 2011. A versão original está disponível na Biblioteca da FMUSP) São Paulo 2017 Dados Internacionais de Catalogação na Publicação (CIP) Preparada pela Biblioteca da Faculdade de Medicina da Universidade de São Paulo ©reprodução autorizada pelo autor Zilli, Renato Wilberto Eficácia em longo prazo das gliflozinas versus gliptinas no tratamento do diabetes mellitus tipo 2 após falência da metformina como monoterapia : revisão sistemática e metanálise em rede / Renato Wilberto Zilli ‐‐ São Paulo, 2017. Tese(doutorado)--Faculdade de Medicina da Universidade de São Paulo. Programa de Ciências Médicas. Área de concentração: Processos Imunes e Infecciosos. Orientador: Fabiano Pinheiro da Silva. Descritores: 1.Diabetes mellitus tipo 2 2.Metanálise 3.Terapia combinada 4.Falha de tratamento 5.Metformina 6.Inibidores da dipeptidil peptidase IV 7.Transportador 2 de glucose‐sódio/inibidores 8.Empagliflozina 9.Dapagliflozina 10.Saxagliptina USP/FM/DBD ‐302/17 Esta tese de doutorado está de acordo com as seguintes normas, em vigor no momento desta publicação: Referências: adaptado de International Committee of Medical Journals Editors (Vancouver). Guia de apresentação e dissertações, teses e monografias. Elaborado por Anneliese Cordeiro da Cunha, Maria Julia de A.L.
    [Show full text]
  • Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis
    International Journal of Molecular Sciences Review Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis Yoshio Sumida 1,* , Masashi Yoneda 1, Katsutoshi Tokushige 2, Miwa Kawanaka 3, Hideki Fujii 4, Masato Yoneda 5, Kento Imajo 5 , Hirokazu Takahashi 6, Yuichiro Eguchi 7, Masafumi Ono 8, Yuichi Nozaki 9 , Hideyuki Hyogo 10, Masahiro Koseki 11, Yuichi Yoshida 12, Takumi Kawaguchi 13 , Yoshihiro Kamada 14, Takeshi Okanoue 15, Atsushi Nakajima 5 and Japan Study Group of NAFLD (JSG-NAFLD) y 1 Division of Hepatology and Pancreatology, Department of Internal Medicine, Aichi Medical University, Nagakute, Aichi 480-1195, Japan; [email protected] 2 Department of Internal Medicine, Institute of Gastroenterology, Tokyo Women’s Medical University, Tokyo 162-8666, Japan; [email protected] 3 Department of General Internal Medicine2, Kawasaki Medical School, Okayama 700-8505, Japan; [email protected] 4 Department of Hepatology, Graduate School of Medicine, Osaka City University, Osaka 558-8585, Japan; [email protected] 5 Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan; [email protected] (M.Y.); [email protected] (K.I.); [email protected] (A.N.) 6 Department of Metabolism and Endocrinology, Faculty of Medicine, Saga University, Saga 840-8502, Japan; [email protected] 7 Liver Center, Saga University Hospital, Saga 840-8502, Japan; [email protected] 8 Division of Gastroenterology and Hepatology,
    [Show full text]
  • Multi-Country Non-Interventional Study on the Effectiveness and Safety of Empagliflozin in Adult Patients with Type 2 Diabetes in Europe and Asia
    ABCD e title PAGE Protocol for non-interventional studies based on existing data TITLE PAGE Document Number: c26457869-02 BI Study Number: 1245.195 BI Investigational Jardiance ® (empagliflozin) Product(s): Title: Multi-country non-interventional study on the effectiveness and safety of Empagliflozin in adult patients with type 2 diabetes in Europe and Asia Protocol version 2.0 identifier: Date of the last version 29 November 2018 of the protocol: PASS: No EU PAS register EUPAS27606 number: Active substance: A10BK03 empagliflozin Medicinal product: Jardiance Product reference: Europe: EMEA/H/C/002677 Asia: NA Procedure number: N/A Joint PASS: No Research question and The main objective of this study is to compare effectiveness objectives: outcomes between the incident users of empagliflozin or any SGLT-2 inhibitor and the incident users of any DPP-4 inhibitor. The effectiveness outcomes include, where available, cardiovascular events, renal effectiveness outcomes, and cardiovascular and all-cause mortality. Additional analyses include safety outcomes. Health care resources utilization and cost of care outcomes will also be evaluated. Countries of study: Denmark, Finland, Germany, Israel, Japan, Norway, South Korea, Spain, Sweden, Taiwan, United Kingdom. Other countries may be included later. 001-MCS-90-124_RD-01 (4.0) Boehringer Ingelheim Page 2 of 132 Protocol for non-interventional studies based on existing data BI Study Number 1245.195 c26457869-02 Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies Author: StatFinn-EPID Research: Ilkka Tamminen, Katja Hakkarainen, Fabian Hoti, Riho Klement, Juha Mehtälä, Laura Saarelainen, Giorgi Tskhvarashvili Harvard Medical School: Elisabetta Patorno, MD, PhD Boehringer Ingelheim: Anouk Déruaz Luyet, PhD Kimberly G.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]
  • WO 2016/016772 Al 4 February 2016 (04.02.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/016772 Al 4 February 2016 (04.02.2016) P O P C T (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/4745 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/IB20 15/055556 KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (22) International Filing Date: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, 22 July 2015 (22.07.2015) PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (25) Filing Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 2422/MUM/2014 26 July 2014 (26.07.2014) IN GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: WOCKHARDT LIMITED [IN/IN]; D-4, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, MIDC Area, Chikalthana, Aurangabad 43 1006 (IN).
    [Show full text]
  • ATC-Index Mit DDD-Angaben Für Deutschland Im Jahr 2020
    Fehler! Kein Text mit angegebener Formatvorlage im Dokument. 1 Uwe Fricke – Judith Günther - Katja Niepraschk- von Dollen – Anette Zawinell Mai 2020 Anatomisch-therapeutisch- chemische Klassifikation mit Tagesdosen für den deutschen Arzneimittelmarkt ATC-Index mit DDD-Angaben GKV-Arzneimittelindex Impressum Die vorliegende Publikation ist ein Beitrag des GKV-Arzneimittelindex im Wissenschaftlichen Institut der AOK (WldO). Anatomisch-therapeutisch-chemische Klassifikation mit Tagesdosen für den deutschen Arzneimittelmarkt ATC-Index mit DDD-Angaben für den deutschen Arzneimittelmarkt Berlin 2020, 19. überarbeitete Auflage Uwe Fricke, Judith Günther, Katja Niepraschk-von Dollen, Anette Zawinell Wissenschaftliches Institut der AOK (WldO) im AOK-Bundesverband GbR Rosenthaler Str. 31, 10178 Berlin Geschäftsführender Vorstand: Martin Litsch (Vorsitzender) Jens Martin Hoyer (stellv. Vorsitzender) http://www.aok-bv.de/impressum/index.html Aufsichtsbehörde: Senatsverwaltung für Gesundheit, Pflege und Gleichstellung –SenGPG– Oranienstraße 106, 10969 Berlin Pharmazeutisch-technische Assistenz: Sandra Heric, Heike Hoffmeister, Sabine Roggan, Manuela Steden Datenverarbeitung: Kenan Ajanovic, Birol Knecht Redaktionelle Bearbeitung: Melanie Hoberg, Manuela Steden Umschlaggestaltung/Design: KomPart Nachdruck, Wiedergabe, Vervielfältigung und Verbreitung (gleich welcher Art), auch von Teilen des Werkes, bedürfen der ausdrücklichen Genehmigung. E-Mail: [email protected] Internet: http://www.wido.de Inhalt Wissenschaftliche Berater des GKV-Arzneimittelindex
    [Show full text]
  • Pharmacokinetic/Pharmacodynamic Interaction Between Evogliptin And
    Pharmacokinetic/Pharmacodynamic Interaction between Evogliptin and Pioglitazone in Healthy Male Subjects Inyoung Hwang1, Yun Kim2, Hyounggyoon Yoo3, In-Jin Jang3, Kyung-Sang Yu4, and SeungHwan Lee2 1Affiliation not available 2Seoul National University College of Medicine and Hospital 3Seoul National University College of Medicine 4Seoul National University Hospital June 15, 2020 Abstract Aims: Evogliptin is a newly developed oral glucose-lowering medication of dipeptidyl peptidase 4 (DPP-4) inhibitor class for type 2 diabetes mellitus. Combination of DPP-4 inhibitor with pioglitazone is a promising therapeutic option. The aim of present study was to evaluate pharmacokinetic and pharmacodynamic interaction between evogliptin and pioglitazone. Methods: A randomized, open-label, multiple-dose, three-treatment, three-period, six-sequence crossover study was conducted in healthy Korean male subjects. All subjects received evogliptin 5 mg once daily for 7 days (EVO), pioglitazone 30 mg once daily for 7 days (PIO) and co-administration of evogliptin 5 mg and pioglitazone 30 mg once daily for 7 days (EVO+PIO) according to the assigned sequence and period. Serial blood samples were collected for 24 hours for pharmacokinetic analysis and 3 hours after oral glucose tolerance test for pharmacodynamic analysis. Results: Thirty-four subjects completed the study. EVO+PIO and EVO showed similar maximum plasma concentration at steady state (Cmax,ss) and the area under the concentration-time curve during dosing interval at steady state (AUCt,sc) of evogliptin, with geometric mean ratios (GMRs) (90% confidence interval (CI)) of 1.01 (0.97-1.05) and 1.01 (0.98-1.04), respectively. EVO+PIO and PIO showed similar Cmax,ss and AUCt,sc of pioglitazone, with GMRs (90% CI) of 1.07 (0.99-1.17) and 1.08 (0.99-1.17), respectively.
    [Show full text]
  • Towards Precision Medicine for Type 2 Diabetes
    Review Current Progress in Pharmacogenetics of Second-Line Antidiabetic Medications: Towards Precision Medicine for Type 2 Diabetes Chan Uk Heo and Chang-Ik Choi * College of Pharmacy, Dongguk University-Seoul, Goyang 10326, Korea; [email protected] * Correspondence: [email protected]; Tel.: +82-31-961-5230 Received: 4 March 2019; Accepted: 18 March 2019; Published: 21 March 2019 Abstract: Precision medicine is a scientific and medical practice for personalized therapy based on patients’ individual genetic, environmental, and lifestyle characteristics. Pharmacogenetics and pharmacogenomics are also rapidly developing and expanding as a key element of precision medicine, in which the association between individual genetic variabilities and drug disposition and therapeutic responses are investigated. Type 2 diabetes (T2D) is a chronic metabolic disorder characterized by hyperglycemia mainly associated with insulin resistance, with the risk of clinically important cardiovascular, neurological, and renal complications. The latest consensus report from the American Diabetes Association and European Association for the Study of Diabetes (ADA-EASD) on the management of T2D recommends preferential use of glucagon-like peptide-1 (GLP-1) receptor agonists, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and some dipeptidyl peptidase-4 (DPP-4) inhibitors after initial metformin monotherapy for diabetic patients with established atherosclerotic cardiovascular or chronic kidney disease, and with risk of hypoglycemia or body weight-related problems. In this review article, we summarized current progress on pharmacogenetics of newer second-line antidiabetic medications in clinical practices and discussed their therapeutic implications for precision medicine in T2D management. Several biomarkers associated with drug responses have been identified from extensive clinical pharmacogenetic studies, and functional variations in these genes have been shown to significantly affect drug-related glycemic control, adverse reactions, and risk of diabetic complications.
    [Show full text]
  • Pharmaceutical Composition for Preventing Or Treating Diabetes, Containing Zinc Salt, Cyclo-Hispro and Antidiabetic Drug As Active Ingredients
    (19) *EP003698801A2* (11) EP 3 698 801 A2 (12) EUROPEAN PATENT APPLICATION published in accordance with Art. 153(4) EPC (43) Date of publication: (51) Int Cl.: 26.08.2020 Bulletin 2020/35 A61K 33/30 (2006.01) A61K 38/43 (2006.01) A61K 31/427 (2006.01) A61K 31/155 (2006.01) (2006.01) (21) Application number: 18867498.0 A61K 31/702 (22) Date of filing: 19.10.2018 (86) International application number: PCT/KR2018/012392 (87) International publication number: WO 2019/078663 (25.04.2019 Gazette 2019/17) (84) Designated Contracting States: • JEON, Jong Su AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Pohang-si GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO Gyeongsangbuk-do 37664 (KR) PL PT RO RS SE SI SK SM TR • KIM, Bo Bae Designated Extension States: Seoul 01368 (KR) BA ME • LEE, Heon Jong Designated Validation States: Incheon 21048 (KR) KH MA MD TN • SONG, Moon Ki Northridge (30) Priority: 20.10.2017 KR 20170136242 California 91326 (US) • LEE, Do Hyun (71) Applicant: Novmetapharma Co., Ltd. Pohang-si Seoul 06050 (KR) Gyeongsangbuk-do 37669 (KR) (72) Inventors: (74) Representative: Dehns • JUNG, Hoe Yune St. Bride’s House Pohang-si 10 Salisbury Square Gyeongsangbuk-do 37668 (KR) London EC4Y 8JD (GB) (54) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETES, CONTAINING ZINC SALT, CYCLO-HISPRO AND ANTIDIABETIC DRUG AS ACTIVE INGREDIENTS (57) The present invention relates to a pharmaceu- tical composition for preventing or treating diabetes, com- prising, as active ingredients: (a) a zinc salt, comprising a zinc cation and anion, and cyclo-hispro, or a pharma- ceutically acceptable salt thereof; and (b) an antidiabetic drug (particularly, an insulin sensitizer, an insulin sensi- tizer, a sodium-glucose co-transporter (a sodium-glu- cose co-transporter 2 (SGLT2) inhibitor), or a DPP-4 in- hibitor).
    [Show full text]
  • Evogliptin Suppresses Calcific Aortic Valve Disease by Attenuating
    cells Article Evogliptin Suppresses Calcific Aortic Valve Disease by Attenuating Inflammation, Fibrosis, and Calcification Bongkun Choi 1,2, Eun-Young Kim 1,2, Ji-Eun Kim 1,2, Soyoon Oh 1,2, Si-On Park 1,2, Sang-Min Kim 1,2, Hyuksu Choi 1,2, Jae-Kwan Song 3,† and Eun-Ju Chang 1,2,4,*,† 1 Department of Biomedical Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea; [email protected] (B.C.); [email protected] (E.-Y.K.); [email protected] (J.-E.K.); [email protected] (S.O.); [email protected] (S.-O.P.); [email protected] (S.-M.K.); [email protected] (H.C.) 2 Stem Cell Immunomodulation Research Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea 3 Division of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea; [email protected] 4 Department of Biochemistry, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea * Correspondence: [email protected] † These authors contributed equally to this study. Abstract: Calcific aortic valve disease (CAVD) accompanies inflammatory cell infiltration, fibro- sis, and ultimately calcification of the valve leaflets. We previously demonstrated that dipeptidyl peptidase-4 (DPP-4) is responsible for the progression of aortic valvular calcification in CAVD ani- mal models. As evogliptin, one of the DPP-4 inhibitors displays high specific accumulation in cardiac tissue, we here evaluated its therapeutic potency for attenuating valvular calcification in CAVD animal models. Evogliptin administration markedly reduced calcific deposition accompanied by a reduction in proinflammatory cytokine expression in endothelial nitric oxide synthase-deficient Citation: Choi, B.; Kim, E.-Y.; Kim, mice in vivo, and significantly ameliorated the mineralization of the primary human valvular in- J.-E.; Oh, S.; Park, S.-O.; Kim, S.-M.; terstitial cells (VICs), with a reduction in the mRNA expression of bone-associated and fibrosis- Choi, H.; Song, J.-K.; Chang, E.-J.
    [Show full text]